Advances in pancreatic cancer research from 2017 annual meeting of the American Society of Clinical Oncology

Pancreatic cancer is one of the most aggressive malignant tumors with dismal prognosis. The 2017 annual meeting of the American Society of Clinical Oncology (ASCO) brings together thousands of oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. In this paper, authors selected and reviewed pancreatic cancer research from 2017 annual meeting of the ASCO, especially the latest research progress in genetic diagnosis, chemotherapy, immunotherapy, targeted therapy and neoadjuvant treatments.